title: Issues related to development of new antiseizure treatments.
abstract: This report represents a summary of the discussions led by the antiseizure treatment working group of the International League Against Epilepsy (ILAE)/American Epilepsy Society (AES) Working Groups joint meeting in London (London Meeting). We review here what is currently known about the pharmacologic characteristics of current models of refractory seizures, both for adult and pediatric epilepsy. In addition, we address how the National Institute of Neurological Disorders and Stroke (NINDS)-funded Anticonvulsant Screening Program (ASP) is evolving to incorporate appropriate animal models in the search for molecules that might be sufficiently novel to warrant further pharmacologic development. We also briefly address what we believe is necessary, going forward, to achieve the goal of stopping seizures in all patients, with a call to arms for funding agencies, the pharmaceutical industry, and basic researchers.
authors.affiliation: Anticonvulsant Drug Development Program, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, Utah 84108, USA. karen.wilcox@hsc.utah.edu
authors.forename: Karen S
authors.initials: KS
authors.lastname: Wilcox
authors.forename: Tracy
authors.initials: T
authors.lastname: Dixon-Salazar
authors.forename: Graeme J
authors.initials: GJ
authors.lastname: Sills
authors.forename: Elinor
authors.initials: E
authors.lastname: Ben-Menachem
authors.forename: H Steve
authors.initials: HS
authors.lastname: White
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Porter
authors.forename: Marc A
authors.initials: MA
authors.lastname: Dichter
authors.forename: Solomon L
authors.initials: SL
authors.lastname: Moshé
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Noebels
authors.forename: Michael D
authors.initials: MD
authors.lastname: Privitera
authors.forename: Michael A
authors.initials: MA
authors.lastname: Rogawski
mesh_terms: D000328:Adult; D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D004195:Disease Models, Animal; D055808:Drug Discovery; D004341:Drug Evaluation; D004345:Drug Industry; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D012109:Research Support as Topic; D057170:Translational Research, Biomedical
chemical_list: D000927:Anticonvulsants; D015507:Drugs, Investigational
keywords: Animal models of epilepsy; Antiseizure drug; Pharmacoresistant epilepsy
references.citation: Brain. 2009 Oct;132(Pt 10):2805-21
references.pmid: 19755519
references.citation: Epilepsy Res. 1999 Feb;33(2-3):199-215
references.pmid: 10094431
references.citation: Epilepsia. 2007 Dec;48(12):2287-95
references.pmid: 17711461
references.citation: J Clin Neurophysiol. 2010 Dec;27(6):418-24
references.pmid: 21076333
references.citation: Epilepsy Res. 1993 Jul;15(3):207-19
references.pmid: 8223417
references.citation: J Physiol. 2008 Jul 15;586(14):3405-23
references.pmid: 18483067
references.citation: Epilepsia. 1995 Feb;36(2):179-85
references.pmid: 7821276
references.citation: Epilepsia. 2006 Jul;47(7):1160-8
references.pmid: 16886979
references.citation: Epilepsy Res. 2010 Jun;90(1-2):47-59
references.pmid: 20435440
references.citation: Ann Neurol. 2003 Apr;53(4):469-79
references.pmid: 12666114
references.citation: Epilepsia. 2010 Jun;51(6):1069-77
references.pmid: 19889013
references.citation: Epilepsia. 2000 Dec;41(12):1514-21
references.pmid: 11114208
references.citation: Epilepsy Res. 1995 Feb;20(2):93-104
references.pmid: 7750514
references.citation: J Pharmacol Exp Ther. 2011 Mar;336(3):779-90
references.pmid: 21123672
references.citation: Nat Neurosci. 2006 Sep;9(9):1142-9
references.pmid: 16921370
references.citation: Neurotherapeutics. 2011 Apr;8(2):304-15
references.pmid: 21431948
references.citation: Arch Pharm (Weinheim). 2011 Apr;344(4):231-41
references.pmid: 21469172
references.citation: Epilepsia. 2012 Oct;53(10):1839-40
references.pmid: 23030262
references.citation: Epilepsia. 1998 Oct;39(10):1046-53
references.pmid: 9776324
references.citation: J Neurosci. 2009 Feb 18;29(7):2103-12
references.pmid: 19228963
references.citation: Epilepsy Behav. 2003 Oct;4(5):457-63
references.pmid: 14527485
references.citation: Brain. 2006 Dec;129(Pt 12):3290-306
references.pmid: 16951410
references.citation: Epilepsia. 2010 Aug;51(8):1385-94
references.pmid: 20491877
references.citation: Br J Pharmacol. 2008 Jun;154(3):709-24
references.pmid: 18414393
references.citation: J Pharmacol Exp Ther. 1953 Mar;107(3):273-83
references.pmid: 13035666
references.citation: Bioorg Med Chem Lett. 2011 Oct 1;21(19):5800-3
references.pmid: 21875804
references.citation: Epilepsia. 2009 Dec;50 Suppl 12:25-6
references.pmid: 19941516
references.citation: Lancet Neurol. 2006 Feb;5(2):189-96
references.pmid: 16426995
references.citation: Epilepsy Curr. 2009 Mar-Apr;9(2):47-52
references.pmid: 19421380
references.citation: Epilepsia. 2012 Oct;53(10):1837-9
references.pmid: 23030261
references.citation: Epilepsia. 1995 Jul;36(7):636-43
references.pmid: 7555978
references.citation: Epilepsy Res. 2000 Jun;40(1):63-77
references.pmid: 10771259
references.citation: Neurobiol Dis. 2010 Mar;37(3):604-12
references.pmid: 19945533
references.citation: Brain Dev. 2013 Sep;35(8):748-56
references.pmid: 23312951
references.citation: Epilepsia. 2000 Apr;41(4):372-9
references.pmid: 10756400
references.citation: J Neurotrauma. 2012 Mar 20;29(5):789-812
references.pmid: 22023672
references.citation: Epilepsy Behav. 2013 Mar;26(3):253-60
references.pmid: 23219411
references.citation: Epilepsy Res. 2010 Aug;90(3):304-8
references.pmid: 20599358
references.citation: Epilepsia. 2012 Oct;53(10):1844-6
references.pmid: 23030267
references.citation: Lancet Neurol. 2012 Sep;11(9):792-802
references.pmid: 22832500
references.citation: Neuroscience. 2002;112(1):101-11
references.pmid: 12044475
references.citation: Handb Clin Neurol. 2012;107:63-98
references.pmid: 22938964
references.citation: Epilepsia. 2005 Jan;46(1):8-14
references.pmid: 15660763
references.citation: Epilepsy Res. 2007 May;74(2-3):97-106
references.pmid: 17395429
references.citation: Epilepsia. 2012 Oct;53(10):1842-3
references.pmid: 23030265
references.citation: Epilepsy Res. 2013 Feb;103(2-3):135-52
references.pmid: 23196211
references.citation: Epilepsia. 2007 Apr;48(4):816-26
references.pmid: 17319923
references.citation: Exp Neurol. 2010 Aug;224(2):369-88
references.pmid: 20420832
references.citation: Neuropharmacology. 2000 Jul 24;39(10):1893-903
references.pmid: 10884570
references.citation: Epilepsia. 2008 Feb;49(2):298-307
references.pmid: 17941850
references.citation: Epilepsia. 2003 Dec;44(12):1472-8
references.pmid: 14636315
references.citation: Epilepsy Res. 2013 Mar;104(1-2):26-34
references.pmid: 23158096
references.citation: Epilepsy Res. 2001 Dec;47(3):217-27
references.pmid: 11738929
references.citation: J Pharmacol Exp Ther. 2013 May;345(2):215-24
references.pmid: 23424217
references.citation: Epilepsia. 2012 Oct;53(10):1843-4
references.pmid: 23030266
references.citation: PLoS One. 2013;8(2):e57445
references.pmid: 23437388
references.citation: J Neurosci. 2009 Jul 8;29(27):8752-63
references.pmid: 19587282
references.citation: Neurotherapeutics. 2012 Jan;9(1):176-84
references.pmid: 22139591
references.citation: Epilepsia. 2002 Apr;43(4):350-7
references.pmid: 11952764
references.citation: Exp Neurol. 2012 Mar;234(1):70-84
references.pmid: 22201552
references.citation: Epilepsy Res. 1995 Feb;20(2):105-11
references.pmid: 7750506
references.citation: Epilepsy Behav. 2008 Jul;13(1):62-9
references.pmid: 18337179
references.citation: Epilepsy Res. 2010 Dec;92(2-3):163-9
references.pmid: 20951004
references.citation: Curr Opin Neurol. 2012 Apr;25(2):159-63
references.pmid: 22274775
references.citation: Dev Neurobiol. 2012 Feb;72(2):186-98
references.pmid: 21692188
references.citation: Epilepsia. 2010 Jul;51 Suppl 3:154-9
references.pmid: 20618423